VMVsevolod Andreevich Misyurin

Vsevolod Andreevich Misyurin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Vsevolod Andreevich Misyurin has a total of 148 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Predictive Modeling of Clinical Trial Outcomes for Novel Drugs using Digital Twin Patient Cohorts and GenerativeAI

    by Dmitrii K Chebanov, Vsevolod A Misyurin

    There is a problem of clinical trial failure, as each new drug should surpass the effectiveness of existing treatment regimens, which becomes increasingly challenging over time. Another significant issue is treating patients who have developed resistance to the current therapies. Essentially, the use of drug combinations or off-label drug use, where the indication does not match the diagnosis, is akin to an experiment, as there is insufficient data on which drug or combination to use. This work proposes an approach utilizing computer modeling of patients using gene expression and clinical data. Deep learning and generative adversarial networks are employed as modeling tools. The training data for the algorithms were sourced from publicly available databases such as TCGA and Drugbank. The modeling is based on the hypothesis of similarity between patients, similarity between drugs, as well as the similarity between individual organs and patient tissues with cell lines, with similarity being computed mathematically. As a result, a patient model is created, where the input consists of drugs and their combinations, and the output provides survival probability values. These model data can be generated in any required quantity with generative adversarial networks (GAN) technology to create observation and control groups. Consequently, it becomes possible to simulate clinical trials, forecasting their outcomes, and, most importantly, optimizing the trial parameters to maximize the likelihood of success.


  • Open Access

    An algorithm for drug discovery based on deep learning with an example of developing a drug for the treatment of lung cancer

    by Dmitrii K. Chebanov, Vsevolod A. Misyurin, Irina Zh. Shubina

    We have designed an algorithm implemented in a software platform for the development of new anti-tumor drugs in the form of small molecules. Several molecules were generated for the treatment of patients with lung cancer as an example. At the initial stage, we identified the targets for the therapy. Firstly, we evaluated the expression profile of the genes most associated with poor clinical outcome in patients with lung cancer using deep learning. Additional patients’ data were gained by generative adversarial neural networks (GAN) technology. As a result, a set of genes was successfully selected, which expression was associated with poor prognosis. We identified the genes that could distinguish normal tissue from tumor tissue using another deep learning model that was trained to predict normal and tumor tissue based on gene expression. The other genes were considered as targets for targeted lung cancer therapy. After that, a module was developed that predicts the interactions of inhibitors with proteins. For this purpose, the amino acid sequences of proteins were represented in vector form, as well as formulas of chemical compounds interacting with proteins. In addition, a deep learning-based module was developed that predicts the IC50 in experiments on cell lines. Virtual pre-clinical trials with the selected inhibitors were performed to identify relevant cell lines for laboratory experiments. As a result, the study obtained formulas of several molecules with the predicted binding to certain proteins.

  • Open Access

    GAGE gene and protein expression profile in cancer patients

    by A. A. Rudakova, A. D. Shirin, N. V. Golubtsova, M. V. Pinyugina, V. A. Misyurin

    Cancer-testis antigens (CTA) are antigens expressed by tumor cells of various histological types, but practically absent in cells of normal tissues, with the exception of germ cells. CTA includes more than 100 proteins, most of which are grouped into large families. Currently, the use of CTA for immunotherapy in the treatment of oncological diseases has been tested in many studies, and an increase in survival time has been achieved for many cases. Therefore, they can be promising targets for the creation of antitumor drugs, targeted therapy of tumors and as diagnostic biomarkers.The purpose of this review was to study the GAGE family of antigens, one of the CTA groups recognized by T cells. Proteins of this family, expressed in tumor cells, stimulate the development of a humoral and cellular immune response against them. It follows from this that they fully meet the requirements for targets for tumor immunotherapy. The review provides information about the structure and sequence of genes encoding proteins of the GAGE family. The question of the role of GAGE in apoptosis is considered in detail and the results of studies proving that GAGE-7C makes cells resistant to apoptosis mediated by interferon γ or Fas are presented. The results of clinical studies of the expression of GAGE group genes and proteins in various types of tumor diseases are considered and examples of the reported correlation between GAGE expression and poor prognosis in some types of cancer are given.Thus, the proteins of the GAGE group, with a detailed study, can become a possible diagnostic and prognostic marker of cancer diseases, and in the future be used to assess malignancy and monitor tumors for the selection of treatment tactics.

  • Open Access

    Aminooxy Click Modification of a Periodate-Oxidized Immunoglobulin G: A General Approach to Antibody–Drug Conjugates with Dye-Mediated Expeditious Stoichiometry Control

    by Ksenia A. Sapozhnikova, Evgeny L. Gulyak, Vladimir A. Brylev, Vsevolod A. Misyurin, Sergey D. Oreshkov, Anastasiya V. Alexeeva, Dmitry Yu. Ryazantsev, Maria A. Simonova, Ekaterina V. Ryabukhina, Galina P. Popova, et al.

    A universal approach to the construction of antibody–drug conjugates (ADCs) has been developed. It relies on periodate oxidation of naturally present glycans of immunoglobulin G, followed by oxime ligation and, optionally, copper(I)-catalyzed alkyne-azide cycloaddition for conjugation with a toxic payload. The introduction of highly absorbing cyanine dyes into the linker allows for facile determination of the drug–antibody ratio. We applied this methodology to the synthesis of cytotoxic conjugates of an antibody against the tumor-associated antigen PRAME with doxorubicin and monomethyl auristatin E (MMAE). The resultant conjugates retained their affinity to a large extent, yet their cytotoxicity in vitro varied dramatically: while the doxorubicin-based conjugate did not produce any effect on cells, the MMAE-based one demonstrated specific activity against PRAME-expressing cancer cell lines. Importantly, the latter conjugate constitutes the first reported example of a PRAME-targeting ADC.


  • Open Access

    Branched Linkers for Site-Specific Fluorescent Labeling of Antibodies

    by Ksenia A. Sapozhnikova, Evgeny L. Gulyak, Vsevolod A. Misyurin, Maria A. Simonova, Ekaterina V. Ryabukhina, Anastasiya V. Alexeeva, Nataliya A. Tikhonova, Natalia A. Lyzhko, Galina P. Popova, Andrey V. Misyurin, et al.

    Fluorescent antibodies have proved to be an invaluable tool for molecular biology and diagnostics. They are routinely produced by modification of lysine residues, which leads to high heterogeneity. As such, their affinity may be compromised if the antigen-binding site is affected, the probability of which increases along with the degree of labeling. In this work, we propose a methodology for the synthesis of site-specific antibody-dye conjugates with a high degree of labeling. To this end, we synthesized two oxyamine-based branched triazide linkers and coupled them with a periodate-oxidized anti-PRAME antibody 6H8; two oxyamine-based linear monoazide linkers of similar structure were used as controls. The azide-labeled antibodies were subsequently conjugated with fluorescent dyes via SPAAC, a copper-free click reaction. Compared to their counterparts made with linear linkers, the branched conjugates possessed a higher degree of labeling. The utility of the methodology was demonstrated in the detection of the PRAME protein on the surface of the cell by flow cytometry.


  • Open Access

    Immunohistochemical analysis of prame expression as a prognostic factor in uveal melanoma patients

    by S. V. Saakyan, A. Yu. Tsygankov, A. G. Amiryan, M. R. Khlgatyan, D. A. Khochenkov, V. A. Misyurin

    The study objective is to analyze the prognostic significance of PRAME protein expression in patients with uveal melanoma using immunohistochemical assay.Materials and methods. A total of 30 patients with uveal melanoma were examined and treated. The average age of patients at the time of treatment was 51.3 ± 11.8 years. In all cases, enucleation was performed according to the indications. A routine clinical-morphological, molecular-genetic, and immunohistochemical assay study was performed (n = 29). The immunohistochemical study was performed using antibodies to PRAME (clone 6H8, dilution 1: 50). The median follow-up period was 86.3 ± 2.9 months.Results. Of the 29 samples studied, staining was determined in 16, which was 55.2 %. Weak intensity of 1+ staining (from 10 to 20 % of tumor cells) was detected in 7 uveal melanoma samples, medium intensity of 2+ (from 10 to 20 % of tumor cells) – also in 7, and strong intensity of 3+ (30 % of tumor cells) – in 2 tumor samples. When assessing the seven-year survival, the cumulative survival rate in the group without PRAME expression was 0.857, while in the group with PRAME expression it was significantly lower and amounted to 0.357 (p = 0.0001). The PRAME protein expression was significantly correlated with the epithelioid cell type of the tumor (p = 0.041) and with the total and partial monosomy of chromosome 3 (p = 0.013).Conclusion. This paper presents the world’s first study of the prognostic significance of PRAME protein expression by immunohistochemical analysis in patients with uveal melanoma. A significant association of PRAME-positive patients with an unfavorable vital prognosis was shown.

  • Open Access

    Sensitive Immunofluorescent Detection of the PRAME Antigen Using a Practical Antibody Conjugation Approach

    by Ksenia A. Sapozhnikova, Vsevolod A. Misyurin, Dmitry Y. Ryazantsev, Egor A. Kokin, Yulia P. Finashutina, Anastasiya V. Alexeeva, Igor A. Ivanov, Milita V. Kocharovskaya, Nataliya A. Tikhonova, Galina P. Popova, et al.

    Bioconjugation of antibodies with various payloads has diverse applications across various fields, including drug delivery and targeted imaging techniques. Fluorescent immunoconjugates provide a promising tool for cancer diagnostics due to their high brightness, specificity, stability and target affinity. Fluorescent antibodies are widely used in flow cytometry for fast and sensitive identification and collection of cells expressing the target surface antigen. Nonetheless, current approaches to fluorescent labeling of antibodies most often use random modification, along with a few rather sophisticated site-specific techniques. The aim of our work was to develop a procedure for fluorescent labeling of immunoglobulin G via periodate oxidation of antibody glycans, followed by oxime ligation with fluorescent oxyamines. Here, we report a novel technique based on an in situ oxime ligation of ethoxyethylidene-protected aminooxy compounds with oxidized antibody glycans. The approach is suitable for easy modification of any immunoglobulin G, while ensuring that antigen-binding domains remain intact, thus revealing various possibilities for fluorescent probe design. The technique was used to label an antibody to PRAME, a cancer-testis protein overexpressed in a number of cancers. A 6H8 monoclonal antibody to the PRAME protein was directly modified with protected-oxyamine derivatives of fluorescein-type dyes (FAM, Alexa488, BDP-FL); the stoichiometry of the resulting conjugates was characterized spectroscopically. The immunofluorescent conjugates obtained were applied to the analysis of bone marrow samples from patients with oncohematological diseases and demonstrated high efficiency in flow cytometry quantification. The approach can be applied for the development of various immunofluorescent probes for detection of diagnostic and prognostic markers, which can be useful in anticancer therapy.


  • Detection of the PRAME Protein on the Surface of Melanoma Cells Using a Fluorescently Labeled Monoclonal Antibody

    by K. A. Sapozhnikova, A. V. Misyurin, N. B. Pestov, E. G. Meleshkina, S. D. Oreshkov, E. P. Ganzhula, A. S. Mikhailova, V. A. Korshun, V. A. Misyurin, V. A. Brylev

    Determination of the expression level of tumor marker PRAME protein is important both for predicting the course of the disease and for monitoring the effectiveness of anticancer therapy. A fluorescently labeled monoclonal antibody to the PRAME protein was obtained by periodate oxidation of glycans followed by modification with a bifunctional azido-oxyamine reagent and a “click” reaction with alkyne-modified sulfonated cyanine dye Cy3. A new approach to the synthesis of a bifunctional azido-oxyamine reagent using the ethoxyethylidene protecting group for oxyamine is proposed. The labeled antibodies were characterized with UV/Vis absorption spectra and the stoichiometry of the modification was determined. It has been demonstrated that the fluorescent antibodies retain affinity and can be used as a diagnostic tool for detecting the residual marker (the PRAME protein) after anticancer therapy.


  • Open Access

    NOVEL IMMUNOTHERAPEUTIC TARGETED GRANZYME DELIVERY SYSTEMS IN TREATMENT OF MALIGNANT TUMORS

    by I. V. Yarosh, V. A. Misyurin, I. I. Krasnyuk

    Cytotoxicity is the main human killer cell property. The cytotoxicity reaction of human killer cells is achieved through a complex of molecules, including perforins, granzyme, cathepsin and others. However, only one molecule is enough for target cell death: granzyme. Other molecules are intended for granzyme activation and its delivery to the target cell cytoplasm. Granzymes are a whole family of serine proteases that perform their function in the human body as integral cytolytic effectors during programmed cell death of cancer and pathogen-infected cells. Secreted mainly by cytotoxic T-lymphocytes and NK-cells, granzymes initiate apoptosis via caspase-dependent and caspase-independent pathways. These natural properties make granzymes one of the most promising human enzymes for use in the development of targeted therapeutic strategies in the treatment of various types of cancer.The most promising is granzyme B, because it has the most powerful effector properties. Due to the initiation of cascade reactions that activate apoptosis, granzyme is attractive as a basis for the development of medicines applicable in clinical oncology. At this time, several approaches have been developed for delivering granzyme molecules to tumor cells and facilitating its penetration through the cell membrane. Moreover, some solutions are proposed to overcome the resistance of target cells to granzyme-mediated apoptosis. These approaches are discussed in this review.The purpose of this review was to systematize information on the use of granzyme B as a nanostructured drug delivery system in the treatment of solid and hematological malignancies. In addition, this review discusses ways to overcome the resistance of granzyme penetration into target cells.

  • Biological features of tissue and bone sarcomas investigated using an in vitro model of clonal selection

    by N.A. Avdonkina, A.B. Danilova, V.A. Misyurin, E.A. Prosekina, D.V. Girdyuk, N.V. Emelyanova, T.L. Nekhaeva, G.I. Gafton, I.A. Baldueva